Luminex Corporation (LMNX) Shares Sold by ProShare Advisors LLC
ProShare Advisors LLC lessened its position in shares of Luminex Corporation (NASDAQ:LMNX) by 2.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,748 shares of the medical instruments supplier’s stock after selling 547 shares during the period. ProShare Advisors LLC owned approximately 0.06% of Luminex Corporation worth $565,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Sei Investments Co. boosted its holdings in shares of Luminex Corporation by 10.9% during the first quarter. Sei Investments Co. now owns 5,946 shares of the medical instruments supplier’s stock worth $110,000 after acquiring an additional 582 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in shares of Luminex Corporation by 6.7% during the first quarter. BNP Paribas Arbitrage SA now owns 7,780 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 489 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Luminex Corporation by 92.1% during the second quarter. State of Alaska Department of Revenue now owns 7,895 shares of the medical instruments supplier’s stock worth $166,000 after acquiring an additional 3,785 shares during the period. Mason Street Advisors LLC boosted its holdings in shares of Luminex Corporation by 0.5% during the first quarter. Mason Street Advisors LLC now owns 8,713 shares of the medical instruments supplier’s stock worth $160,000 after acquiring an additional 46 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Luminex Corporation by 37.4% during the second quarter. SG Americas Securities LLC now owns 9,726 shares of the medical instruments supplier’s stock worth $205,000 after acquiring an additional 2,649 shares during the period. Institutional investors own 77.95% of the company’s stock.
Shares of Luminex Corporation (NASDAQ:LMNX) opened at 20.77 on Thursday. Luminex Corporation has a 52-week low of $17.64 and a 52-week high of $23.62. The stock has a 50 day moving average of $19.56 and a 200-day moving average of $19.86. The firm has a market capitalization of $915.35 million, a P/E ratio of 64.30 and a beta of 0.29.
Luminex Corporation (NASDAQ:LMNX) last released its quarterly earnings data on Monday, August 7th. The medical instruments supplier reported $0.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.11. The company had revenue of $76.50 million during the quarter, compared to the consensus estimate of $75.45 million. Luminex Corporation had a net margin of 4.72% and a return on equity of 4.81%. Luminex Corporation’s revenue for the quarter was up 19.2% on a year-over-year basis. During the same period last year, the firm earned $0.33 EPS. Equities analysts expect that Luminex Corporation will post $0.53 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 22nd will be issued a $0.06 dividend. This represents a $0.24 annualized dividend and a yield of 1.16%. The ex-dividend date is Thursday, September 21st. Luminex Corporation’s dividend payout ratio (DPR) is presently 75.00%.
ILLEGAL ACTIVITY WARNING: “Luminex Corporation (LMNX) Shares Sold by ProShare Advisors LLC” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/luminex-corporation-lmnx-shares-sold-by-proshare-advisors-llc/1609449.html.
A number of brokerages have recently issued reports on LMNX. ValuEngine upgraded Luminex Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Zacks Investment Research upgraded Luminex Corporation from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective for the company in a report on Thursday, August 24th. BidaskClub cut Luminex Corporation from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 9th. TheStreet cut Luminex Corporation from a “b” rating to a “c+” rating in a report on Monday, August 7th. Finally, Jefferies Group LLC restated a “hold” rating and set a $21.00 price objective on shares of Luminex Corporation in a report on Friday, June 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. Luminex Corporation currently has a consensus rating of “Hold” and a consensus target price of $21.40.
In related news, Director Robert J. Cresci sold 19,631 shares of the firm’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $18.98, for a total value of $372,596.38. Following the completion of the transaction, the director now directly owns 260,358 shares of the company’s stock, valued at approximately $4,941,594.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is currently owned by company insiders.
About Luminex Corporation
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.